Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

K Rejeski, A Burchert, G Iacoboni, P Sesques… - Blood …, 2022 - ashpublications.org
CD19 CAR T-cells represent a practice-changing treatment modality for advanced B-cell
malignancies. However, refractory cytopenias have emerged as a potentially life-threatening …
被引用次数：41 相关文章

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

K Rejeski, A Burchert, G Iacoboni, P Sesques… - Blood …, 2022 - europepmc.org
The advent of chimeric antigen receptor T-cell therapy (CAR-T) has substantially improved
clinical outcomes for refractory B-cell malignancies. 1-4 Real-world evidence has underlined …

[引用][C] Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

K Rejeski, A Burchert, G Iacoboni, P Sesques… - Blood advances, 2022 - ddd.uab.cat
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after
CD19 CAR T-cell therapy - Dipòsit Digital de Documents de la UAB visitant :: identificació …

[引用][C] Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

P Barba, K Rejeski, A Burchert, G Iacoboni… - Blood …, 2022 - portalrecerca.uab.cat
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after
CD19 CAR T-cell therapy — Universitat Autònoma de Barcelona Research Portal Skip to main …

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

K Rejeski, A Burchert, G Iacoboni… - Blood …, 2022 - pubmed.ncbi.nlm.nih.gov
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after
CD19 CAR T-cell therapy Safety and feasibility of stem cell boost as a salvage therapy for …
[HTML] nih.gov

[HTML][HTML] Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

K Rejeski, A Burchert, G Iacoboni, P Sesques… - Blood …, 2022 - ncbi.nlm.nih.gov
The advent of chimeric antigen receptor T-cell therapy (CAR-T) has substantially improved
clinical outcomes for refractory B-cell malignancies. 1-4 Real-world evidence has underlined …